Evaluating the Conjugatability of ADC Drug-Linker Impurities to Develop Process & Impurity Control Strategies

2:45 pm - Tuesday 9th March 2027

  • Highlighting the importance of evaluating the “conjugatability” of drug linker-derived impurities
  • Demonstrating the use of LC-MS/MS and derivatization to efficiently assess impurity conjugatability without full structural identification
  •  Illustrating how conjugatability assessment can provide scientific insights to develop process optimisation and impurity control

Speakers:

Scientist
Astellas Pharma